▶ 調査レポート

バイオシミラーの世界市場:製品別(組換グリコシル化タンパク質[モノクローナル抗体、エリスロポエチン、その他]、組換非グリコシル化タンパク質[インスリン、顆粒球コロニー刺激因子、組換ヒト成長因子、インターフェロン]、組換ペプチド)、適応症別(慢性疾患、腫瘍学、自己免疫疾患、感染症、血液疾患、成長ホルモン欠乏症、その他)

• 英文タイトル:Biosimilars Market (Product: Recombinant Glycosylated Proteins [Monoclonal Antibodies, Erythropoietin, and Others], Recombinant Non-glycosylated Proteins [Insulin, Granulocyte Colony Stimulating Factor, Recombinant Human Growth Factor, and Interferons], and Recombinant Peptides; and Indication: Chronic Diseases, Oncology, Autoimmune Diseases, Infectious Diseases, Blood Disorders, Growth Hormone Deficiency, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Transparency Market Researchが調査・発行した産業分析レポートです。バイオシミラーの世界市場:製品別(組換グリコシル化タンパク質[モノクローナル抗体、エリスロポエチン、その他]、組換非グリコシル化タンパク質[インスリン、顆粒球コロニー刺激因子、組換ヒト成長因子、インターフェロン]、組換ペプチド)、適応症別(慢性疾患、腫瘍学、自己免疫疾患、感染症、血液疾患、成長ホルモン欠乏症、その他) / Biosimilars Market (Product: Recombinant Glycosylated Proteins [Monoclonal Antibodies, Erythropoietin, and Others], Recombinant Non-glycosylated Proteins [Insulin, Granulocyte Colony Stimulating Factor, Recombinant Human Growth Factor, and Interferons], and Recombinant Peptides; and Indication: Chronic Diseases, Oncology, Autoimmune Diseases, Infectious Diseases, Blood Disorders, Growth Hormone Deficiency, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 / D0JU09026資料のイメージです。• レポートコード:D0JU09026
• 出版社/出版日:Transparency Market Research / 2020年1月8日
• レポート形態:英文、PDF、232ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥857,660 (USD5,795)▷ お問い合わせ
  Multi User¥1,301,660 (USD8,795)▷ お問い合わせ
  Corporate License¥1,745,660 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、バイオシミラーの世界市場について調査・分析し、序論、仮定、調査手法、エグゼクティブサマリー、市場動向、市場概要、製品別(組換グリコシル化タンパク質[モノクローナル抗体、エリスロポエチン、その他]、組換非グリコシル化タンパク質[インスリン、顆粒球コロニー刺激因子、組換ヒト成長因子、インターフェロン]、組換ペプチド)分析、適応症別(慢性疾患、腫瘍学、自己免疫疾患、感染症、血液疾患、成長ホルモン欠乏症、その他)分析、地域別分析、競争状況などの構成でお届けいたします。
・序論
・仮定
・調査手法
・エグゼクティブサマリー
・市場動向
・市場概要
・バイオシミラーの世界市場:製品別(組換グリコシル化タンパク質[モノクローナル抗体、エリスロポエチン、その他]、組換非グリコシル化タンパク質[インスリン、顆粒球コロニー刺激因子、組換ヒト成長因子、インターフェロン]、組換ペプチド)
・バイオシミラーの世界市場:適応症別(慢性疾患、腫瘍学、自己免疫疾患、感染症、血液疾患、成長ホルモン欠乏症、その他)
・バイオシミラーの世界市場:地域別
・競争状況

Biosimilars Market – Scope of the Report

TMR’S report on the global biosimilars market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market during the forecast period of 2019 to 2027. The report provides the overall market revenue of the global biosimilars market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global biosimilars market for the forecast period.

The report has been prepared after an extensive research. Primary research involves bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global biosimilars market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have also employed a combination of the top-down and bottom-up approaches to study various phenomena in the global biosimilars market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competitive dynamics in the global biosimilars market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global biosimilars market. The next section of the global biosimilars report highlights the USPs, which include regulatory scenarios for biosimilars globally, Biosimilars pipeline analysis, and potential product launches in the global biosimilars market.

The report delves into the competitive landscape of the global biosimilars market. Key players operating in the global biosimilars market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the global biosimilars market report.

Key Questions Answered in Biosimilars Market Report

What is the sales/revenue generated by biosimilar products across all regions during the forecast period?
What are the key trends in the biosimilars market?
What are the major drivers, restraints, and opportunities in the market?
In which region is the biosimilars market set to expand at the fastest CAGR during the forecast period?
Which segment will have the highest revenue globally in 2027 and which product segment will expand at the fastest CAGR during the forecast period?
Biosimilars Market – Research Objectives and Research Approach

The comprehensive report on the global biosimilars market begins with an overview of the said market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of this study and healthcare compliances laid down by accredited agencies in the purview of research in the biosimilars market. It is followed by market introduction, market dynamics, and an overview of the biosimilars market, which includes TMR analysis of market drivers, restraints, and trends affecting the growth of the market. Furthermore, Y-o-Y analysis with elaborate insights has been provided to understand the Y-o-Y trends of the biosimilars market. The next section of the biosimilars report highlights the USPs, which include regulatory scenarios for biosimilars globally, biosimilars pipeline analysis, and key product launches in the global market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into small sections. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Revenue generated by key biosimilars market manufacturers have been mapped to ascertain the size of the global biosimilars market in terms of value. The forecast presented here assesses the total revenue generated in the biosimilars market. In order to provide an accurate forecast, we initiated by sizing up the current biosimilars market with the help of the parent market.

The report analyzes the biosimilars market in terms of product, indication, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2027 has been provided. These valuable insights would help market stakeholders in making informed business decisions for investments in the biosimilars market.

レポート目次

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Acronyms

3. Research Methodology

4. Executive Summary: Global Biosimilars Market

5. Market Overview

5.1. Definition

5.2. Market Indicators

5.3. Market Dynamics

5.3.1. Drivers

5.3.2. Restraints

5.3.3. Opportunities

6. Market Outlook

6.1. Global Biosimilars Market Analysis and Forecast, 2017–2027

6.2. Global Biosimilars Market Outlook

6.3. Entry Barriers to Biosimilars Market

6.4. Factors Driving the Adoption of Biosimilars

6.5. Pipeline Analysis

6.6. Regulatory Scenario Assessment

6.7. Key Industry Developments

7. Global Biosimilars Market Analysis and Forecast, by Product

7.1. Introduction

7.2. Biosimilars Market Value Forecast, by Product, 2017–2027

7.2.1. Recombinant Glycosylated Proteins

7.2.1.1. Monoclonal Antibodies

7.2.1.2. Erythropoietin

7.2.1.3. Others

7.2.2. Recombinant Non-glycosylated Proteins

7.2.2.1. Insulin

7.2.2.2. Granulocyte Colony Stimulating Factor

7.2.2.3. Recombinant Human Growth Factor

7.2.2.4. Interferons

7.2.3. Recombinant Peptides

7.3. Market Attractiveness, by Product

8. Global Biosimilars Market Analysis and Forecast, by Indication

8.1. Introduction

8.2. Biosimilars Market Value Forecast, by Indication, 2017–2027

8.2.1. Chronic Diseases

8.2.2. Oncology

8.2.3. Autoimmune Diseases

8.2.4. Infectious Diseases

8.2.5. Blood Disorders

8.2.6. Growth Hormone Deficiency

8.2.7. Others

8.3. Market Attractiveness By Material

9. Global Biosimilars Market Analysis and Forecast, by Region

9.1. Regional Outlook

9.2. Global Scenario

9.3. Introduction

9.4. Biosimilars Market Value Forecast, by Region

9.4.1. North America

9.4.2. Europe

9.4.3. Asia Pacific

9.4.4. Latin America

9.4.5. Middle East & Africa

9.5. Market Attractiveness, by Region

10. North America Biosimilars Market Analysis and Forecast

10.1. Key Findings

10.2. North America Biosimilars Market Value Forecast, by Product, 2017–2027

10.2.1. Recombinant Glycosylated Proteins

10.2.1.1. Monoclonal Antibodies

10.2.1.2. Erythropoietin

10.2.1.3. Others

10.2.2. Recombinant Non-glycosylated Proteins

10.2.2.1. Insulin

10.2.2.2. Granulocyte Colony Stimulating Factor

10.2.2.3. Recombinant Human Growth Factor

10.2.2.4. Interferons

10.2.3. Recombinant Peptides

10.3. North America Biosimilars Market Value Forecast, by Indication, 2017–2027

10.3.1. Chronic Diseases

10.3.2. Oncology

10.3.3. Autoimmune Diseases

10.3.4. Infectious Diseases

10.3.5. Blood Disorders

10.3.6. Growth Hormone Deficiency

10.3.7. Others

10.4. North America Biosimilars Market Value Forecast, by Country, 2017–2027

10.4.1. U.S.

10.4.2. Canada

10.5. North America Biosimilars Market Attractiveness Analysis

10.5.1. By Product

10.5.2. By Indication

10.5.3. By Country

11. Europe Biosimilars Market Analysis and Forecast

11.1. Key Findings

11.2. Europe Biosimilars Market Value Forecast, by Product, 2017–2027

11.2.1. Recombinant Glycosylated Proteins

11.2.1.1. Monoclonal Antibodies

11.2.1.2. Erythropoietin

11.2.1.3. Others

11.2.2. Recombinant Non-glycosylated Proteins

11.2.2.1. Insulin

11.2.2.2. Granulocyte Colony Stimulating Factor

11.2.2.3. Recombinant Human Growth Factor

11.2.2.4. Interferons

11.2.3. Recombinant Peptides

11.3. Europe Biosimilars Market Value Forecast, by Indication, 2017–2027

11.3.1. Chronic Diseases

11.3.2. Oncology

11.3.3. Autoimmune Diseases

11.3.4. Infectious Diseases

11.3.5. Blood Disorders

11.3.6. Growth Hormone Deficiency

11.3.7. Others

11.4. Europe Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2027

11.4.1. U.K.

11.4.2. Germany

11.4.3. France

11.4.4. Italy

11.4.5. Spain

11.4.6. Rest of Europe

11.5. Europe Biosimilars Market Attractiveness Analysis

11.5.1. By Product

11.5.2. By Indication

11.5.3. By Country/Sub-region

12. Asia Pacific Biosimilars Market Analysis and Forecast

12.1. Key Findings

12.2. Asia Pacific Biosimilars Market Value Forecast, by Product, 2017–2027

12.2.1. Recombinant Glycosylated Proteins

12.2.1.1. Monoclonal Antibodies

12.2.1.2. Erythropoietin

12.2.1.3. Others

12.2.2. Recombinant Non-glycosylated Proteins

12.2.2.1. Insulin

12.2.2.2. Granulocyte Colony Stimulating Factor

12.2.2.3. Recombinant Human Growth Factor

12.2.2.4. Interferons

12.2.3. Recombinant Peptides

12.3. Asia Pacific Biosimilars Market Value Forecast, by Indication, 2017–2027

12.3.1. Chronic Diseases

12.3.2. Oncology

12.3.3. Autoimmune Diseases

12.3.4. Infectious Diseases

12.3.5. Blood Disorders

12.3.6. Growth Hormone Deficiency

12.3.7. Others

12.4. Asia Pacific Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2027

12.4.1. China

12.4.2. India

12.4.3. Japan

12.4.4. Australia & New Zealand

12.4.5. Rest of Asia Pacific

12.5. Asia Pacific Biosimilars Market Attractiveness Analysis

12.5.1. By Product

12.5.2. By Indication

12.5.3. By Country/Sub-region

13. Latin America Biosimilars Market Analysis and Forecast

13.1. Key Findings

13.2. Latin America Biosimilars Market Value Forecast, by Product, 2017–2027

13.2.1. Recombinant Glycosylated Proteins

13.2.1.1. Monoclonal Antibodies

13.2.1.2. Erythropoietin

13.2.1.3. Others

13.2.2. Recombinant Non-glycosylated Proteins

13.2.2.1. Insulin

13.2.2.2. Granulocyte Colony Stimulating Factor

13.2.2.3. Recombinant Human Growth Factor

13.2.2.4. Interferons

13.2.3. Recombinant Peptides

13.3. Latin America Biosimilars Market Value Forecast, by Indication, 2017–2027

13.3.1. Chronic Diseases

13.3.2. Oncology

13.3.3. Autoimmune Diseases

13.3.4. Infectious Diseases

13.3.5. Blood Disorders

13.3.6. Growth Hormone Deficiency

13.3.7. Others

13.4. Latin America Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2027

13.4.1. Brazil

13.4.2. Mexico

13.4.3. Rest of Latin America

13.5. Latin America Biosimilars Market Attractiveness Analysis

13.5.1. By Product

13.5.2. By Indication

13.5.3. By Country/Sub-region

14. Middle East & Africa Biosimilars Market Analysis and Forecast

14.1. Key Findings

14.2. Middle East & Africa Biosimilars Market Value Forecast, by Product, 2017–2027

14.2.1. Recombinant Glycosylated Proteins

14.2.1.1. Monoclonal Antibodies

14.2.1.2. Erythropoietin

14.2.1.3. Others

14.2.2. Recombinant Non-glycosylated Proteins

14.2.2.1. Insulin

14.2.2.2. Granulocyte Colony Stimulating Factor

14.2.2.3. Recombinant Human Growth Factor

14.2.2.4. Interferons

14.2.3. Recombinant Peptides

14.3. Middle East & Africa Biosimilars Market Value Forecast, by Indication, 2017–2027

14.3.1. Chronic Diseases

14.3.2. Oncology

14.3.3. Autoimmune Diseases

14.3.4. Infectious Diseases

14.3.5. Blood Disorders

14.3.6. Growth Hormone Deficiency

14.3.7. Others

14.4. Middle East & Africa Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2027

14.4.1. GCC Countries

14.4.2. South Africa

14.4.3. Rest of Middle East & Africa

14.5. Middle East & Africa Biosimilars Market Attractiveness Analysis

14.5.1. By Product

14.5.2. By Indication

14.5.3. By Country/Sub-region

15. Competition Landscape

15.1. Competition Matrix

15.2. Market Share Analysis, by Company, 2018

15.3. Company Profiles

15.3.1. Pfizer, Inc.

15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.1.2. Financial Overview

15.3.1.3. Product Portfolio

15.3.1.4. Strategic Overview

15.3.1.5. SWOT Analysis

15.3.2. Intas Pharmaceuticals Ltd.

15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.2.2. Financial Overview

15.3.2.3. Product Portfolio

15.3.2.4. Strategic Overview

15.3.2.5. SWOT Analysis

15.3.3. Biocon

15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.3.2. Financial Overview

15.3.3.3. Product Portfolio

15.3.3.4. Strategic Overview

15.3.3.5. SWOT Analysis

15.3.4. Dr. Reddy’s Laboratories Ltd.

15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.4.2. Financial Overview

15.3.4.3. Product Portfolio

15.3.4.4. Strategic Overview

15.3.4.5. SWOT Analysis

15.3.5. Teva Pharmaceutical Industries Ltd.

15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.5.2. Financial Overview

15.3.5.3. Product Portfolio

15.3.5.4. Strategic Overview

15.3.5.5. SWOT Analysis

15.3.6. Sandoz International GmbH (A Novartis Division)

15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.6.2. Financial Overview

15.3.6.3. Product Portfolio

15.3.6.4. Strategic Overview

15.3.6.5. SWOT Analysis

15.3.7. Celltrion Inc.

15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.7.2. Financial Overview

15.3.7.3. Product Portfolio

15.3.7.4. Strategic Overview

15.3.7.5. SWOT Analysis

15.3.8. Amgen, Inc.

15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.8.2. Financial Overview

15.3.8.3. Product Portfolio

15.3.8.4. Strategic Overview

15.3.8.5. SWOT Analysis

15.3.9. STADA Arzneimittel AG

15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.9.2. Financial Overview

15.3.9.3. Product Portfolio

15.3.9.4. Strategic Overview

15.3.9.5. SWOT Analysis

15.3.10. Apotex Inc. (Apobiologix)

15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.10.2. Financial Overview

15.3.10.3. Product Portfolio

15.3.10.4. Strategic Overview

15.3.10.5. SWOT Analysis

List of Tables

Table 01: Pipeline Analysis – Biosimilars

Table 02: Global Biosimilars Market Value (US$ Mn) Forecast, by Product, 2017–2027

Table 03: Global Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Glycosylated Proteins, 2017–2027

Table 04: Global Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2027

Table 05: Global Biosimilars Market Value (US$ Mn) Forecast, by Indication, 2017–2027

Table 06: Global Biosimilars Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 07: North America Biosimilars Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 08: North America Biosimilars Market Value (US$ Mn) Forecast, by Product Type, 2017–2027

Table 09: North America Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Glycosylated Proteins, 2017–2027

Table 10: North America Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2027

Table 11: North America Biosimilars Market Value (US$ Mn) Forecast, by Indication, 2017–2027

Table 12: Europe Biosimilars Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 13: Europe Biosimilars Market Value (US$ Mn) Forecast, by Product Type, 2017–2027

Table 14: Europe Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Glycosylated Proteins, 2017–2027

Table 15: Europe Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2027

Table 16: Europe Biosimilars Market Value (US$ Mn) Forecast, by Indication, 2017–2027

Table 17: Asia Pacific Biosimilars Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 18: Asia Pacific Biosimilars Market Value (US$ Mn) Forecast, by Product, 2017–2027

Table 19: Asia Pacific Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Glycosylated Proteins, 2017–2027

Table 20: Asia Pacific Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2027

Table 21: Asia Pacific Biosimilars Market Value (US$ Mn) Forecast, by Indication, 2017–2027

Table 22: Latin America Biosimilars Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 23: Latin America Biosimilars Market Value (US$ Mn) Forecast, by Product, 2017–2027

Table 24: Latin America Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Glycosylated Proteins, 2017–2027

Table 25: Latin America Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2027

Table 26: Latin America Biosimilars Market Value (US$ Mn) Forecast, by Indication, 2017–2027

Table 27: Middle East & Africa Biosimilars Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 28: Middle East & Africa Biosimilars Market Value (US$ Mn) Forecast, by Product, 2017–2027

Table 29: Middle East & Africa Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Glycosylated Proteins, 2017–2027

Table 30: Middle East & Africa Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2027

Table 31: Middle East & Africa Biosimilars Market Value (US$ Mn) Forecast, by Indication, 2017–2027